KYKOF News and Press, Kyowa Hakko Kogyo From 08/27/19

The FDA approves Kyowa Kirin's ( OTCPK:KYKOF ) Nourianz (istradefylline) tablets as an add-on treatment to levodopa/carbidopa for adults with Parkinson's disease (PD) who are experiencing "off" episodes. More news on: Kyowa Kirin Co., Ltd., Healthcare stocks news, Read more ...

AVEO Oncology (NASDAQ: AVEO ) and Kyowa Kirin Co., Ltd. ( OTCPK:KYKOF ) have amended their license agreement allowing the latter to repurchase the non-oncology rights to tivozanib in AVEO territories, including the U.S. and EU. Under their original 2006 contract, AVEO had exclusive rights ...

The FDA accepts for review Kyowa Hakko Kirin Co., Ltd.'s ( OTCPK:KYKOF ) resubmitted marketing application seeking approval for istradefylline, a selective adenosine A 2A  receptor antagonist, as an adjunct to levodopa/carbidopa in adult Parkinson's disease patients experiencing "OFF"...

Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Clovis's portents of irrelevance not recognized by the company, presses on with combo stu...

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. The world of biotech investing revolves first and foremost around the regulatory agencies like th...

The following slide deck was published by Kyowa Hakko Kogyo Co., Ltd. ADR in conjunction with their 2017 Q4 earnings Read more ...